Literature DB >> 6236917

Specific allogeneic help by T lymphocytes from patients with systemic lupus erythematosus.

M K Hari Kumar, R A Knight, M L Snaith.   

Abstract

Unfractionated mononuclear cells from patients with systemic lupus erythematosus (SLE) immunized with influenza vaccines do not produce a secondary in vitro anti-influenza antibody response when challenged with virus antigen. Irradiated T lymphocytes from normal, disease control and from SLE donors whether vaccinated or not, help allogeneic normal non-T cells to produce specific anti-influenza antibody in vitro. Irradiated normal T cells, however, do not help allogeneic non-T cells from SLE donors. Non-irradiated T cells from 40% of the SLE patients, irrespective of whether or not they had been vaccinated, also provide specific help for MLC incompatible normal non-T cells in the influenza antibody response. This non-restricted interaction was not seen using non-irradiated T cells from any normal or disease control donor. No anti-DNA antibodies were produced in virus stimulated cultures of non-irradiated or irradiated SLE T cells with allogeneic normal non-T cells.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6236917      PMCID: PMC1576965     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  18 in total

1.  Hypothesis: a model for generalised autoimmunity.

Authors:  P Bretscher
Journal:  Cell Immunol       Date:  1973-01       Impact factor: 4.868

2.  Lymphocyte function in rheumatic disorders.

Authors:  J H Vaughan; T Chihara
Journal:  Arch Intern Med       Date:  1975-10

3.  Chronic graft versus host disease presenting with polymyositis.

Authors:  N Pier; V Dubowitz
Journal:  Br Med J (Clin Res Ed)       Date:  1983-06-25

4.  Histocompatibility requirements for T cell help in specific in vitro antibody responses to influenza virus by human blood lymphocytes.

Authors:  R E Callard; C M Smith
Journal:  Eur J Immunol       Date:  1981-03       Impact factor: 5.532

5.  Distinctive functional characteristics of human "T" lymphocytes defined by E rosetting or a monoclonal anti-T cell antibody.

Authors:  P C Beverley; R E Callard
Journal:  Eur J Immunol       Date:  1981-04       Impact factor: 5.532

6.  Increased immunoglobulin-secreting cells in the blood of patients with active systemic lupus erythematosus.

Authors:  R M Blaese; J Grayson; A D Steinberg
Journal:  Am J Med       Date:  1980-09       Impact factor: 4.965

7.  Studies of immune functions of patients with systemic lupus erythematosus. T-cell subsets and antibodies to T-cell subsets.

Authors:  T Sakane; A D Steinberg; J P Reeves; I Green
Journal:  J Clin Invest       Date:  1979-11       Impact factor: 14.808

8.  Anti-SS-A antibody and other antinuclear antibodies in systemic lupus erythematosus.

Authors:  E Scopelitis; J J Biundo; M A Alspaugh
Journal:  Arthritis Rheum       Date:  1980-03

9.  Responder T cells depleted of alloreactive cells react to antigen presented on allogeneic macrophages from nonresponder strains.

Authors:  N Ishii; C N Baxevanis; Z A Nagy; J Klein
Journal:  J Exp Med       Date:  1981-09-01       Impact factor: 14.307

10.  Evolutionary conservation of surface molecules that distinguish T lymphocyte helper/inducer and cytotoxic/suppressor subpopulations in mouse and man.

Authors:  J A Ledbetter; R L Evans; M Lipinski; C Cunningham-Rundles; R A Good; L A Herzenberg
Journal:  J Exp Med       Date:  1981-02-01       Impact factor: 14.307

View more
  2 in total

Review 1.  Immunisation of patients with rheumatoid arthritis and systemic lupus erythematosus.

Authors:  L Turner-Stokes; D A Isenberg
Journal:  Ann Rheum Dis       Date:  1988-07       Impact factor: 19.103

2.  In vitro response to influenza immunisation by peripheral blood mononuclear cells from patients with systemic lupus erythematosus and other autoimmune diseases.

Authors:  L Turner-Stokes; G Cambridge; T Corcoran; J S Oxford; M L Snaith
Journal:  Ann Rheum Dis       Date:  1988-07       Impact factor: 19.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.